2-氯-4-苯基烟腈 | 163563-64-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-4-苯基烟腈
• 中文别名: 2-氯-4-苯基-3-吡啶甲腈；2-氯-4,6-二苯基烟腈
• 英文名称: 2-Chloro-4-phenyl-3-pyridinecarbonitrile
• 英文别名: 2-chloro-4-phenylnicotinonitrile；2-chloro-4-phenylpyridine-3-carbonitrile
• CAS: 163563-64-2
• 化学式: C₁₂H₇ClN₂
• mdl: MFCD01935958
• 分子量: 214.654
• InChiKey: GYTQTBOCDGGMRW-UHFFFAOYSA-N

物化性质

• 熔点：
  125-127.5°
• 沸点：
  387.4±42.0 °C(Predicted)
• 密度：
  1.30

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-4-phenylnicotinonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-4-phenylnicotinonitrile
CAS number: 163563-64-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H7ClN2
Molecular weight: 214.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-4-苯基烟腈 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 17.0h， 以84%的产率得到4-苯基-1H-吡唑并[3,4-b]吡啶-3-基胺
  参考文献：
  名称：

  [EN] (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS
  [FR] (AZA)PYRIDOPYRAZOLOPYRIMIDINONES ET INDAZOLOPYRIMIDINONES UTILISÉES COMME INHIBITEURS DE LA FIBRINOLYSE

  摘要：

  本申请涉及新型取代的(氮杂)吡啶吡唑吡嘧啶酮和吲唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性出血性疾病的患者的急性和复发性出血，其中出血与来自以下组中选择的疾病或医疗干预相关，该组包括月经过多、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤。

  公开号：

  WO2015067549A1
• 作为产物：
  描述：

  2-(1-苯基亚丙基)丙二腈 在 potassium fluoride 、 natural phosphate 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以91%的产率得到2-氯-4-苯基烟腈
  参考文献：
  名称：

  Zahouily, Mohamed; Bahlaouan, Bouchaib; Abrouki, Younes, Journal of Chemical Research, 2006, # 1, p. 34 - 36

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY<br/>[FR] INHIBITEURS DE TRYPTOPHANE DIOXYGÉNASES (IDO1 ET TDO) ET LEUR UTILISATION EN THÉRAPIE
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2016024233A1

  公开（公告）日：2016-02-18

  Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.

  描述了包含具有IDO1和/or TDO抑制活性的3-氨基异恶唑啉化合物I的药物组合物，其中W是CR1，N或N-氧化物；X是CR2，N或N-氧化物；Y是CR3，N或N-氧化物；Z是CR4，N或N-氧化物；W、X、Y和Z中的至少一个是N或N-氧化物；R9和R10如所定义。还描述了使用这些化合物治疗各种疾病，如癌症的方法。
• (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150126449A1

  公开（公告）日：2015-05-07

  The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代的(氮杂)吡啶吡唑吡嘧啶酮和吲唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性出血性疾病的患者的急性和复发性出血，其中出血与来自月经过多、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血和血液性关节积血后的滑膜炎和软骨损伤等疾病或医疗干预有关。
• Exploring structural effects in a new class of NRF2 inhibitors
  作者：Zhilin Hou、Lizbeth Lockwood、Di Zhang、Christopher J. Occhiuto、Linqing Mo、Kelly E. Aldrich、Hayden E. Stoub、Kathleen A. Gallo、Karen T. Liby、Aaron L. Odom

  DOI：10.1039/d2md00211f

  日期：——

  leads to resistance to chemotherapeutics and promotes metastasis. As a result, inhibition of the NRF2 pathway is a target for new drugs, especially for use in conjunction with established chemotherapeutic agents like carboplatin and 5-fluorouracil. A new class of NRF2 inhibitors has been discovered with substituted nicotinonitriles, such as MSU38225. In this work, the effects on NRF2 inhibition with structural

  NRF2 是一种转录因子，控制细胞对各种应激源（例如活性氧和氮）的反应。因此，它在抑制癌发生方面发挥着关键作用，但癌细胞中的组成型 NRF2 表达会导致对化疗药物的抵抗并促进转移。因此，抑制 NRF2 通路是新药的目标，特别是与卡铂和 5-氟尿嘧啶等现有化疗药物联合使用。已发现一类新的 NRF2 抑制剂，其具有取代的烟腈，例如 MSU38225。在这项工作中，探讨了结构变化对 NRF2 抑制的影响。通过这些研究，我们发现了一些化合物的活性与最初的目标相同或更好，但溶解度大大提高。该合成涉及多种金属催化反应，包括钛多组分偶联反应以及各种Pd和Cu偶联反应。除了抑制 NRF2 活性外，这些新化合物还抑制 NRF2 通路被组成性激活的肺癌细胞的增殖和迁移。
• Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：US10888567B2

  公开（公告）日：2021-01-12

  Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.

  描述了包含具有 IDO1 和/或 TDO 抑制活性的式 I 的 3-氨基异噁唑吡啶化合物的药物组合物，其中 W 是 CR1、N 或 N-氧化物；X 是 CR2、N 或 N-氧化物；Y 是 CR3、N 或 N-氧化物；Z 是 CR4、N 或 N-氧化物；W、X、Y 和 Z 中至少有一个是 N 或 N-氧化物；R9 和 R10 如所定义。 还描述了使用此类化合物治疗各种疾病（如癌症）的方法。
• 芳香乙烯类化合物、其金属络合物及其制备方法和应用
  申请人：上海再极医药科技有限公司

  公开号：CN116332909A

  公开（公告）日：2023-06-27

  本发明公开了一种芳香乙烯类化合物、其金属络合物及其制备方法和应用。该芳香乙烯类化合物的结构如通式II中所示。本发明的芳香乙烯类化合物及其金属络合物对PD‑1/PD‑L1结合具有抑制活性，从而能够用于治疗肿瘤等相关疾病。此外，本发明的金属络合物还能够用作显像剂。